Ashish Dwary
Hematology & Oncology · Medford, ORNPI 1649561473
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $23,798 of the $35,863 with a category attached, or 66.4%. 25 manufacturers reported payments, led by AstraZeneca at 45.3% of the total. 2025 is the largest year on record at $16,664, more than ten times the $1,050 reported in 2020. Among hematology & oncology clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $551.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$16K
- Exelixis Inc.$4K
- G1 Therapeutics, Inc.$3K
- Geron Corporation$3K
- GSK$2K
- Karyopharm Therapeutics Inc.$2K
- plus $7K from 19 others
What the payments were for
- Consulting fees$23,79866%
- Speaking & faculty fees$7,95022%
- Travel & lodging$3,3689%
- Food & beverage$6982%
- Education$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $16,233 |
| Exelixis Inc. | 14 | $3,551 |
| G1 Therapeutics, Inc. | 2 | $3,000 |
| Geron Corporation | 10 | $2,654 |
| GSK | 2 | $1,965 |
| Karyopharm Therapeutics Inc. | 3 | $1,821 |
| Pfizer | 1 | $1,250 |
| Daiichi Sankyo Inc. | 2 | $1,200 |
| Immunomedics, Inc. | 1 | $1,050 |
| Incyte Corporation | 1 | $860 |
| Beigene USA, Inc. | 1 | $525 |
| Beigene, Ltd. | 1 | $525 |
| EMD Serono, Inc. | 1 | $500 |
| Cardinal Health 110 LLC | 1 | $275 |
| Sobi, Inc | 1 | $200 |
| Amgen | 1 | $36 |
| Gilead(2 entities) | 2 | $36 |
| Sanofi | 1 | $36 |
| Astellas Pharma US Inc | 1 | $32 |
| AbbVie | 1 | $27 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| Merck | 1 | $18 |
| Novartis | 1 | $17 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,863 in reported general payments places this provider in the 90th percentile of 112 hematology & oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 39 | $774,724 |
| VenclextaVenetoclax | 38 | $413,562 |
| CalquenceAcalabrutinib Maleate | 25 | $316,833 |
| Lenalidomide | 16 | $200,424 |
| ImbruvicaIbrutinib | 15 | $184,719 |
| Abiraterone Acetate | 72 | $97,736 |
| OrgovyxRelugolix | 23 | $60,078 |
| EliquisApixaban | 86 | $57,055 |
| OxycontinOxycodone Hcl | 11 | $6,123 |
| Enoxaparin Sodium | 23 | $5,390 |
| Imatinib Mesylate | 15 | $4,704 |
| Fentanyl | 28 | $2,677 |
| Letrozole | 89 | $1,603 |
| Oxycodone Hcl | 84 | $1,313 |
| Anastrozole | 66 | $1,198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $3,551 | $774,72439 claims |
| AbbVieVenclexta | $27 | $413,56238 claims |
| AstraZenecaCalquence | $16,233 | $316,83325 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $17 | $184,71915 claims |
| PfizerEliquis | $1,250 | $57,05586 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 112 hematology & oncology providers in Oregon.
Other hematology & oncology in Medford
- Mujahid RizviMedford$11K
- Sara MatarMedford$2K
- Aleksandra SanderMedford$1K
- Hidong KimMedford$1K
- Emre KocaMedford$1K
- Sandra TaylorMedford$1K
- Pragathi BalakrishnaMedford$985
- Tariq KhreisMedford$847
- Alison SavageMedford$730
- Brett PoissonMedford$709
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.